BUTALBITAL, ASPIRIN AND CAFFEINE
Clinical safety rating: avoid
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Aspirin irreversibly inhibits cyclooxygenase-1 and -2, reducing prostaglandin and thromboxane synthesis, leading to analgesic and antipyretic effects. Caffeine is a methylxanthine that antagonizes adenosine receptors, causing vasoconstriction and enhancing analgesia.
| Metabolism | Butalbital: hepatic via CYP2C19 and other CYP enzymes; Aspirin: hepatic hydrolysis to salicylic acid, then conjugation with glycine (salicyluric acid) and glucuronic acid; Caffeine: hepatic via CYP1A2 (major), CYP2E1, and CYP3A4. |
| Excretion | Aspirin (salicylate) is excreted primarily renally (50–80% as free salicylate and metabolites including salicyluric acid, gentisic acid, and glucuronide conjugates), with dose-dependent kinetics. Butalbital is renally excreted (60–70% as unchanged drug and metabolites, primarily 5-allyl-5-isobutylbarbituric acid). Caffeine is renally excreted (1–3% unchanged, 70–80% as paraxanthine, theobromine, theophylline, and their glucuronides). Biliary/fecal excretion is negligible for all components. |
| Half-life | Aspirin (low dose): 2–3 hours; at high doses or in overdose, elimination half-life may prolong to 15–30 hours due to saturation of hepatic conjugation. Butalbital: 35–55 hours (mean ~45 h) with extensive accumulation on repeated dosing. Caffeine: 3–7 hours in healthy adults; prolonged in liver disease or pregnancy. |
| Protein binding | Aspirin (salicylate): 80–90% bound to albumin (saturable at high concentrations). Butalbital: 26–35% bound to plasma proteins (mainly albumin). Caffeine: 10–35% bound (low affinity to albumin). |
| Volume of Distribution | Aspirin (salicylate): 0.15–0.2 L/kg (low, reflects extensive plasma binding). Butalbital: 0.7–1.0 L/kg (moderate distribution into total body water). Caffeine: 0.5–0.7 L/kg (distributes into total body water). |
| Bioavailability | Oral: Aspirin 50–80% (extensive first-pass hydrolysis to salicylate, absolute bioavailability depends on formulation). Butalbital: approximately 90% (minimal first-pass effect). Caffeine: nearly 100% (complete absorption, minimal first-pass). |
| Onset of Action | Oral: Aspirin analgesia onset 15–30 minutes; caffeine CNS stimulation onset 15–45 minutes; butalbital sedation onset 30–60 minutes. |
| Duration of Action | Aspirin analgesia 3–6 hours; caffeine stimulation 3–5 hours; butalbital sedation 4–6 hours. Duration of headache relief typically 4–6 hours per dose. With repeated use, butalbital accumulation may prolong sedative effects. |
| Molecular Weight | Butalbital: 224.26 Da; Aspirin: 180.16 Da; Caffeine: 194.19 Da |
1-2 tablets (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg) orally every 4 hours as needed, not to exceed 6 tablets per day.
| Dosage form | TABLET |
| Renal impairment | For GFR 10-50 mL/min: avoid due to aspirin accumulation; GFR <10 mL/min: contraindicated. |
| Liver impairment | Child-Pugh Class A: caution, use lowest effective dose; Child-Pugh Class B: avoid; Child-Pugh Class C: contraindicated. |
| Pediatric use | Not recommended for pediatric patients due to aspirin and butalbital risks (Reye syndrome, dependence). |
| Geriatric use | Initiate at lowest effective dose (e.g., 1 tablet every 6 hours); monitor for renal function, cognitive impairment, and fall risk. |
| 1st trimester | Avoid. Aspirin associated with increased risk of gastroschisis; caffeine may be used in moderation; butalbital is a potential teratogen. Use only if benefit outweighs risk. |
| 2nd trimester | Avoid. Aspirin in high doses may affect maternal hemostasis; butalbital may cause neonatal withdrawal; caffeine use should be limited. |
| 3rd trimester | Contraindicated. Aspirin increases risk of premature closure of ductus arteriosus and oligohydramnios; butalbital may cause neonatal depression and withdrawal; caffeine may cause neonatal irritability. |
Clinical note
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
| FDA category | Positive |
| Placental transfer | All three components cross the placenta. Butalbital exhibits high placental transfer; aspirin (salicylate) crosses extensively; caffeine crosses readily. |
■ FDA Black Box Warning
None
| Common Effects | fever |
| Serious Effects |
Hypersensitivity to any componentAcute porphyriaSevere hepatic impairmentSevere renal impairmentBleeding disorders (e.g., hemophilia, thrombocytopenia)Concurrent use of anticoagulantsGastrointestinal ulceration or bleedingThird trimester of pregnancyChildren with chickenpox or influenza-like illness (risk of Reye's syndrome)
| Precautions | Risk of Reye syndrome with aspirin in children/teenagers with viral illness; respiratory depression with butalbital, especially with CNS depressants; risk of dependence and withdrawal with butalbital; increased bleeding risk with aspirin; avoid in pregnancy (third trimester due to premature ductus arteriosus closure; aspirin may cause fetal harm); hypersensitivity to NSAIDs. |
| Food/Dietary |
Loading safety data…
| Breastfeeding | Butalbital is excreted into breast milk in low amounts but may cause sedation, poor feeding, or withdrawal in neonates. Aspirin is excreted and may pose a risk of Reye's syndrome if infant has viral illness. Caffeine is excreted and may cause irritability. Use is generally not recommended; avoid if possible. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Aspirin associated with increased risk of gastroschisis; butalbital is a barbiturate with potential teratogenicity (cleft lip/palate, cardiovascular defects) based on limited human data. Second/third trimester: Aspirin use may cause premature closure of ductus arteriosus, oligohydramnios, and intracranial hemorrhage in neonate; butalbital may cause neonatal withdrawal and respiratory depression; chronic high-dose aspirin increases risk of peripartum hemorrhage. |
| Fetal Monitoring | Monitor maternal renal function (aspirin effect), signs of bleeding (gum, nose, bruising), fetal ultrasound for ductus arteriosus closure (second/third trimester), amniotic fluid volume, and fetal growth. Neonatal monitoring for withdrawal (butalbital) and coagulopathy (aspirin). |
| Fertility Effects | Aspirin may inhibit ovulation at high doses via prostaglandin synthesis inhibition; effect reversible. Caffeine may delay conception with high intake (>300 mg/day). Butalbital may cause menstrual irregularities via enzyme induction altering sex hormone metabolism. |
| Avoid alcohol; may increase sedation and risk of gastrointestinal bleeding. Limit additional caffeine-containing foods or beverages (e.g., coffee, tea, cola) to avoid excessive caffeine intake. |
| Clinical Pearls | Butalbital, aspirin, and caffeine combination is indicated for tension-type headache. Monitor for signs of medication overuse headache, especially with frequent use. Aspirin increases bleeding risk; avoid in patients with bleeding disorders or peptic ulcer disease. Butalbital is a barbiturate with potential for dependence; limit to short-term use. Caffeine can potentiate both analgesic effects and side effects like insomnia or tremor. |
| Patient Advice | Do not take more than prescribed; overuse can lead to rebound headaches or dependence. · Avoid alcohol while taking this medication. · Aspirin increases bleeding risk; stop use before surgery or dental procedures. · Do not drive or operate heavy machinery until you know how butalbital affects you. · Limit caffeine intake from other sources to avoid excessive stimulation. · Seek medical help if you experience signs of bleeding, allergic reaction, or severe drowsiness. |